Kyowa Kirin tie-up bolsters Lundbeck's Parkinson's portfolio
This article was originally published in Scrip
Executive Summary
Lundbeck has acquired exclusive rights to develop and commercialise in markets outside Asia an early-stage adenosine A2A antagonist discovered by Japan's Kyowa Hakko Kirin.